Enzo Biochem to buy Belgium's 10 P's BVBA
US firm Enzo Biochem says that its wholly-owned subsidiary Enzo Life Sciences has signed a letter of intent to acquire 10 P's BVBA, a privately-owned distributor of life science research products, with offices in Belgium serving the Benelux countries. Upon completion of the deal, which is subject to definitive agreements, Enzo will have a local, directly-owned presence from which to market its growing line of life sciences reagents and systems. The acquisition, financial terms of which are not disclosed, is expected to close in February 2008.
"This proposed acquisition is one more step in our plan to build Enzo Life Sciences into a major participant in the research products global marketplace," said Barry Weiner, president of Enzo. "Our intention is to continue to evaluate and consummate additional acquisitions that fit in with the infrastructure we have built for this division," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze